Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

About this update from Jaguar Health, Inc.

[{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare Investor Summit.","length":273,"tagName":"p"},{"type":"text","content":"Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Healthcare Investor Summit","length":114,"tagName":"p","attribs":{}},{"type":"text","content":"When: Thursday, January 15, 2026 at 3:30 PM Eastern","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"Registration link for conference: Click Here","length":44,"tagName":"p","attribs":{}},{"type":"text","content":"Replay: A replay of the webcast will be available through the same link (Click Here)","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"About the Jaguar Health Family of Companies","length":43,"tagName":"p"},{"type":"text","content":"Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.","length":1329,"tagName":"p"},{"type":"text","c...

More updates from Jaguar Health, Inc.